



MEDBOX.ORG

COVID-19 | Issue Brief

The MEDBOX team publishes issue briefs on different topics around COVID-19. We would be pleased to receive feedback on this issue brief or topics you would like to see covered in future issues. Registered MEDBOX users can see the latest documents in the 'My News' section by selecting their personal preferences under 'My Profile'.

COVID-19 & Vaccination

Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies, implementation of the vaccination, ethical considerations, as well as educational materials in English and other languages. Additional documents and information are available in the <u>Covid-19 Toolbox</u> under the <u>'Vaccination & Strategy</u>' section.

Useful resources in MEDBOX

Access & Strategy Plans

Guidance on developing a national deployment and vaccination Planning for COVID-19 vaccines *World Health Organization (2020)*

The Guidance on National Deployment and Vaccination Planning is intended to help countries develop their plan for COVID-19 vaccine introduction.

https://medbox.org/document/guidance-on-developing-a-national-deployment-and-vaccination-planning-for-covid-19-vaccines

WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination World Health Organization WHO (2020)

The WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination is intended to offer guidance on the prioritization of groups for vaccination when vaccine supply is limited. It provides a values foundation for the objectives of COVID-19 vaccination programmes and links those to target groups for vaccination. This information is valuable to countries and globally while specific policies will be developed once vaccines become available.

This document it available in Arabic, Chinese, English and Russia

https://medbox.org/document/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination



14 September 2020	World Heat
Status Lateray The Value moves due paines given by the Value of Park Status and Status status and Status and and Status and Status and Status and Status status and Status and Sta	shirtship, shirt sugars, at some starter some some some some some some some some some some some some

COVID-19 Vaccine Development and Access Strategy African Union; Africa CDC Centres for Disease Control and Prevention (2020)

Successful immunization of a critical mass of the African population with one or several safe and efficacious COVID-19 vaccines. Key objectives: 1.Accelerate African involvement in the clinical development of a vaccine. 2. Ensure African countries can access a sufficient share of the global vaccine supply.3. Remove barriers to widespread delivery and uptake of effective vaccines across Africa.

This document is available in Arabic, English, French and Portuguese

https://medbox.org/document/covid-19-vaccine-development-and-access-strategy

COVAX Initiative

Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO (2021)

WHO, UNICEF, Gavi and partners are working together to help prepare countries to be ready to introduce a COVID-19 vaccine.

https://medbox.org/document/covax-initiative

Adaptable guidance, tools, trainings, and advocacy materials are being developed to support countries in preparing for COVID-19 vaccination.

Please visit this page regularly for updates.

https://www.who.int/initiatives/act-accelerator/covax

Readiness

Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19 World Health Organization WHO (2020)

A module from the suite of health service capacity assessments in the context of the COVID-19 pandemic, Interim Guidance 20 November 2020. This tool was developed to ensure the provision of health products for COVID-19 patients in designated COVID-19 facilities. It allows health facilities to assess the availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to identify areas that need further attention to enable the facility to respond effectively to the pandemic.

https://medbox.org/document/diagnostics-therapeutics-vaccine-readiness-and-other-health-products-for-covid-19

COVID-19 Vaccine Country Readiness Assessment Tool (VIRAT) World Health Organization WHO, UNICEF and World Bank (2020)

The COVID-19 Vaccine Introduction Readiness Assessment Tool (VIRAT)2, developed by WHO in collaboration with PAHO is a tool for the national authorities, that allows for the establishment of a roadmap and to monitor progress in the preparation of the activities related to the introduction of the COVID-19 vaccines.

https://medbox.org/document/covid-19-vaccine-country-readiness-assessment-tool-virat









PAHO SECO	<u>6 20</u> 11		THE SERVE READER HER - HER -
	Country Readiness Assessme	nt Tool (VIRAT)	
	The Constant is a large of the first interaction of the Section of	er #16 protes signi 5 formulation #1	the sector for the sector of automotive, that about for the sectors in sectors.
And a second sec		1.12 Norscand National	accused index.
	Sharks 🕴 Child IV Income		
Beng Mark 10 (mr) Hanne Mark 10 Hanne Mark 10 Hanne Mark 10 Hanne Mark 10 Hanne Mark 10 Hanne Mark 10 Hanne Hann Hann	Help and antices (respinance was to 10) respinance (respinance (respinance)) (respinance) (respinance)	Accurate Colonaria (mos Mala and California Mala and California Ma	View V 1 1 II II II II II II

Immunization Guidelines

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing World Health Organization (WHO) 2021

Interim guidance, 8 January 2021

https://medbox.org/document/interim-recommendations-for-use-of-the-pfizerbiontech-covid-19-vaccine-bnt162b2-under-emergency-use-listing

COVID-19: the green book, chapter 14a (Provisional guidance subject to MHRA approval of vaccine supply) Medicines and Healthcare products Regulatory Agency (MHRA) UK (2020)

This chapter includes information on: the coronavirus (COVID-19) vaccines the dosage and schedule for the UK recommendations for the use of the vaccine.

https://medbox.org/document/covid-19-the-green-book-chapter-14a-provisional-guidance-subject-to-mhra-approval-of-vaccine-supply

Immunization in the context of COVID-19 pandemic World Health Organisation (2020)

Immunizations are an essential health service that protect susceptible individuals from vaccine-preventable diseases (VPD).2 By providing timely immunizations, individuals and communities remain protected and the likelihood of a VPD outbreak decreases. This publication is available in Arabic, Chinese, English, French, Russian and Spanish

https://medbox.org/document/immunization-in-the-context-of-covid-19-pandemic

Communication & Information

Behavioural considerations for acceptance and uptake of COVID-19 vaccines *World Health Organization*

WHO technical advisory group on behavioural insights and sciences for health, meeting report, 15 October 2020

https://medbox.org/document/behavioural-considerations-for-acceptance-and-uptake-of-covid-19-vaccines

Corona Crash Course Unit 5: Vaccine Jesuit Worldwide Learning (2020)

In this unit we will learn about vaccines and what is the progress made for developing a vaccine for COVID-19 Jesuit Worldwide Learning invites you to learn facts and test your knowledge on the ongoing pandemic caused by Coronavirus (COVID 19) through a fun-interactive crash course! Access is free! You have only to sign up.

https://medbox.org/document/corona-crash-course-unit-5-vaccine









Questions and answers on COVID-19 vaccine African Union; Africa CDC Centres for Disease Control and Prevention (2020)

How do vaccines work? Fact sheet

https://medbox.org/document/questions-and-answers-on-covid-19-vaccine

<image><image><image><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header>

Videos

The Pfizer Coronavirus Vaccine: How Does It Work? *Shinar, S. (2020)*

Learn about the science behind the new coronavirus vaccine made by Pfizer. This video goes over how vaccines work, and how the Pfizer vaccine is a bit different from most other virus vaccines.

https://medbox.org/document/the-pfizer-coronavirus-vaccine-how-does-it-work

WHO Video Series: Science in 5 World Health Organization

WHO Science in 5: Episode #5 – Vaccines https://medbox.org/document/who-science-in-5-episode-5-vaccines

WHO Science in 5: Episode #15 - COVID-19 - Vaccine distribution https://medbox.org/document/whos-science-in-5-episode-15-covid-19-vaccine-distribution

WHO Science in 5: Episode #16 - COVID-19 - How do vaccines work? https://medbox.org/document/who-science-in-5-episode-16-covid-19-how-do-vaccines-work

WHO Science in 5: Episode #17 - COVID-19 - Vaccine approval https://medbox.org/document/whos-science-in-5-episode-17-covid-19-vaccine-approval

WHO Science in 5: Episode #20 - COVID-19 - Variants & Vaccines <u>https://medbox.org/document/who-science-in-5-episode-20-covid-19-variants-vac-cines</u>

There are more interesting videos to discover in "Science in 5" <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/</u> <u>science-in-5</u>

Resource Platforms

COVID-19 vaccines World Health Oganization (WHO)

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines







Vaccines Kamradt, T., and B.S. Kamps (2021)

As of 8 January, three vaccines had been approved in Europe and in the US: tozinameran (Comirnaty[™]) by BioNTech/Pfizer (formerly known as BNT162b2), mRNA-1273 by Moderna and ChAdOx1 nCoV-19 by University of Oxford/AstraZeneca. Adverse events such as pain at injection site, fatigue, headache, myalgia and fever were common, but serious adverse events were rare. All three vaccines seem to have a favorable safety profile.

https://medbox.org/document/vaccines

Vaccine Candidates

Coronavirus Vaccine Tracker

Zimmer, C, J. Corum and S. Wee (2020)

New York Times. Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 61 vaccines in clinical trials on humans, and 17 have reached the final stages of testing.

https://medbox.org/document/coronavirus-vaccine-tracker

Draft landscape of COVID-19 candidate vaccines World Health Organization WHO (2020)

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).

https://medbox.org/document/draft-landscape-of-covid-19-candidate-vaccines

Africa CDC Consortium for COVID-19 Vaccine Clinical Trials (CONCVACT) African Union; Africa CDC Centres for Disease Control and Prevention (2020)

The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficacy of the most promising vaccine candidates among the region's populations. Also available in French & Portuguese.

https://medbox.org/document/africa-cdc-consortium-for-covid-19-vaccine-clinical-trials-concvact

Moral Aspects

Vaccine: A Paper from the Vatican COVID-19 Commission and the Pontifical Academy for Life *Vatican (2021)*

Vatican lays out 20 points for a universal and fair destination of vaccines, for a fairer and healthier world.

https://medbox.org/document/vaccine-a-paper-from-the-vatican-covid-19-commissionand-the-pontifical-academy-for-life











Scientific Paper

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine *Polack, F.P. et al. (2020)*

This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577

https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=featured_home

PFIZER-BIONTECH COVID-19 Vaccine (BNT162, PF-07302048). Vaccines and related biological products Advisory Committee Briefing Document MEETING DATE: 10 December 2020 *PFIZER-BIONTECH*

https://www.fda.gov/media/144246/download

The UK has approved a COVID vaccine — here's what scientists now want to know *The Nature*

https://www.nature.com/articles/d41586-020-03441-8

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., et al.

The Lancet 2020 Dec 8;S0140-6736(20)32661-1. doi: 10.1016/S0140-6736(20)32661-1. Online ahead of print.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext

A DOLARD	R SEMANAR		
Safety and Efficacy of the BNT	162b2 mRNA (Covid-19 Va	ccine
GUNCAL PROFESS Safe and effective services to preserve server requirence syndrome consensations 2 (2020-Car-Ca bifutions and code) (9 are suppress product. No worknow fore prover against histomenetories are a service workship, and mSSA-based vaccions have not here widely toool. CUNCAL PERM.	7	1	Ī
A sandomiand, double-blind study of an mRNA sources - mandime the Satisfactual A andre mension			
43,540 perfolgement 255 centre old werte molgened to menter the standars or plantice by intermendalar injustion or days and day 25, frantisperor wert followed for safety and law the development of sprogrammin Consil 19 for a median of 2 mentiles.			7
	1	2220	
May. Variant straphents had local matcions spain, exprisents, seedings and exemute maximum (e.g., first, bashadae, multiplicit at higher news than plottle recipions, with more maximum influencing the second dates, then were add up to determ and marked explicit.	1-		-
15em	170033		
The transiste showed anne surly presention 12 days after the fore door. I days after the anneal door. Why offerer		Deputer New 1	
na dearei.		BAT ADA Passing	Plante
OR TATIONS AND INMOUNTS QUELTINGS	Symptomatic Caroli 24		10
hather andy is required to andersond the following	Sores Card-28		
 Indep and officars beyond 2 months and in groups not included in this toil tr.g., shiften, prepare worses, and immenorementaries and present. 	Nocise afflorg of 95%	Million (1997)	4,963-87455
 Hierder the samine potents against asymptomatic infections and transituncion to associated periods. 	0000000000		
 Here to dial with these who miss the around variance door. 	Two-doors of an ARD a module of sevence against assignments are at ables.		

Pfizer		
PEZZR-BONTECH COVID-19 VACCINE (INTIK), PF-0302040)		
VACUNES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMET	nε	
BREFING DOCUMENT		
MEETENG DATE: 10 December 2020		

Pice Baltink



	Articles	
afety and efficacy of the ChAdOx1 nCoV-19 vaccine NZD1222) against SARS-CoV-2: an interim analysis of zon randomised controlled trials in Boail, South Africa, nd the UK	>8\@	
or least, Jose Sanchard, Jankishka Zahali, Ankala Mandari, Kan Kang, Kanang Yao, Jahi, Sanchard Januari, Kanang Yao, Yao, Yao, Yao, Yao, Yao, Yao, Yao,	<u>0.8</u>	
Appendix Is which and efficiency section against action acids supported, publicles constantion 1 (2018) GOV(2), if played which high memory, acade constrainer in the constraint if the OCNMD Paparities. We endowed the outer and act of this OCNMD endoy Processing in a public biometric acids in differential.		
Image allows and the included sequences in COUP IP is summighter participants with a starble and information of participants and and the induction of the information of the information of the measurement of with their and its New ALEE training of their was allowed as 1 induction of the first of their sequences and of distances in the information of the COURTED-In and Christian Spectra Uncertainty, and Uncertainty and Uncertainty.	Marine States	
where there are first of the scale $\{0,1\}$ of the participant on a model and $\{0,1\}$ are imported for the last $\{1,1\}$ and $\{1,1\}$ are imported for a scale $\{1,1\}$ and $\{1,1\}$ are imported for a scale $\{1,1\}$ and $\{1,1\}$ are imported for a scale $\{1,1\}$ are imported for a scale $\{1,1\}$ and $\{1,1\}$ are imported for a scale are imported for a sc	Cong No. Annual St. A Alamatic A Agentic A Agentic	
represention Christolis allocities has an acceptable advar profile and has been found to be efficience against represents (COVID-07-to-this insteam analysis of segrency-finitarities).		
(b) El Reserch and Inservation, National Institutes for Huddli Research (2010), Califies for Epidemic spendence Inservations, BH & Mellach Cates Frankeline, Issuess Frankeline, Reich 1997, Boro and Miler andrian. NUM Huberli Research Ecosity, Humon Yoldy and South Milland's MIRE Uncode Research Work, and Intelligence.	A Company of Company o	
er of a bit for behaving holder in florie tel. No is a fiper home with order to COM of home	Application of Solution	



Medical Mission Institute Würzburg

Catholic Advisory Organisation for International Health

MEDBOX. THE AID LIBRARY Medical Mission Institute

Salvatorstr. 7, 97074 Würzburg, Germany

sieglinde.mauder@medmissio.de